Osteogenic differentiation of human mesenchymal stem cells from adipose tissue and Wharton’s jelly of the umbilical cord

Zajdel, Alicja; Kałucka, Magdalena; Kokoszka-Mikołaj, Edyta; Wilczok, Adam

doi:10.18388/abp.2016_1488

Cited by 56 publications

(32 citation statements)

References 21 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high degree of calcification in AT-MSCs and PDL-MSCs demonstrates that calcium deposition was better as compared to WJ-MSCs for generating vascularized bone grafts [ 61 ]. Similar findings were reported by [ 84 ] where AD-MSCs were found to be superior to WJ-MSCs in terms of differentiating into the osteogenic lineage after 21 days compared. In a different study by Lim and colleagues, MSCs derived from different parts of the umbilical cord, i.e., the fetal, middle, and maternal segments, have the ability to differentiate into osteogenic lineage cells using the osteogenic medium consisting of dexamethasone, ascorbic acid, and β -glycerophosphate.…”

Section: Discussionsupporting

confidence: 90%

Osteogenic Induction of Wharton’s Jelly-Derived Mesenchymal Stem Cell for Bone Regeneration: A Systematic Review

Ansari

Yazid

Sainik

et al. 2018

Stem Cells International

View full text Add to dashboard Cite

Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are emerging as a promising source for bone regeneration in the treatment of bone defects. Previous studies have reported the ability of WJ-MSCs to be induced into the osteogenic lineage. The purpose of this review was to systematically assess the potential of WJ-MSC differentiation into the osteogenic lineage. A comprehensive search was conducted in Medline via Ebscohost and Scopus, where relevant studies published between 1961 and 2018 were selected. The main inclusion criteria were that articles must be primary studies published in English evaluating osteogenic induction of WJ-MSCs. The literature search identified 92 related articles, but only 18 articles met the inclusion criteria. These include two animal studies, three articles containing both in vitro and in vivo assessments, and 13 articles on in vitro studies, all of which are discussed in this review. There were two types of osteogenic induction used in these studies, either chemical or physical. The studies demonstrate that WJ-MSCs are able to differentiate into osteogenic lineage and promote osteogenesis. In light of these observations, it is suggested that WJ-MSCs can be a potential source of stem cells for osteogenic induction, as an alternative to bone marrow-derived mesenchymal stem cells.

show abstract

Section: Discussionsupporting

confidence: 90%

Osteogenic Induction of Wharton’s Jelly-Derived Mesenchymal Stem Cell for Bone Regeneration: A Systematic Review

Ansari

Yazid

Sainik

et al. 2018

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…Indeed, Wharton's jelly MSCs are endowed with high trilineage potential and thus are important for tissue repair and regeneration. In line with the results of (Zajdel et al 2017), OSX, BSP, OPG, OPN and Runx2 were more expressed in ALDH ? cells suggesting that this population clearly owned more capacities to differentiate into osteoclasts than ALDHcells.…”

Section: Discussionsupporting

confidence: 79%

Aldehyde dehydrogenase activity of Wharton jelly mesenchymal stromal cells: isolation and characterization

et al. 2019

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) are promising tools in regenerative medicine and targeted therapies. Although different origins have been described, there is still huge need to find a valuable source harboring specific subpopulations of MSCs with precise therapeutic functions. Here, we isolated by fluorescence activated cell sorting technique, two populations of Wharton's jelly (WJ)-MSCs based on their aldehyde dehydrogenase (ALDH) activity. Two different ALDH activities (low vs. high) were thus observed. We then analyzed their gene expression profile for stemness, phenotype, response to hypoxia, angiogenesis, hematopoietic support, immunomodulation and multilineage differentiation abilities (osteogenesis, adipogenesis, and chondrogenesis). According to ALDH activity, many differences in the mRNA expression of these populations were noticed. In conclusion, we provide evidences that WJ harbors two distinct populations of MSCs with different ALDH activity. These populations seem to display specific functional competences that may be interesting for concise therapeutic applications.

show abstract

“… 3 The choice of MSC tissue source is important both for the type of tissue to regenerate and the biological activity required of the cells in the damaged target tissue. For example, it is known that adipose tissue and umbilical cord MSCs give origin to adipogenic, 71 chondrogenic, 72 and osteogenic 73 lineages. MSC sources can also influence basic cellular features such as surface cellular markers and size.…”

Section: Main Textmentioning

confidence: 99%

Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation

Salvadori

Cesari

Murgia

et al. 2019

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

Recently, mesenchymal stromal stem cells (MSCs) have been proposed as therapeutic agents because of their promising preclinical features and good safety profile. However, their introduction into clinical practice has been associated with a suboptimal therapeutic profile. In this review, we address the biodistribution of MSCs in preclinical studies with a focus on the current understanding of the pharmacodynamics (PD) and pharmacokinetics (PK) of MSCs as key aspects to overcome unsatisfactory clinical benefits of MSC application. Beginning with evidence of MSC biodistribution and highlighting PK and PD factors, a new PK-PD model is also proposed. According to this theory, MSCs and their released factors are key players in PK, and the efficacy biomarkers are considered relevant for PD in more predictive preclinical investigations. Accounting for the PK-PD relationship in MSC translational research and proposing new models combined with better biodistribution studies could allow realization of the promise of more robust MSC clinical translation.

show abstract

Osteogenic differentiation of human mesenchymal stem cells from adipose tissue and Wharton’s jelly of the umbilical cord

Cited by 56 publications

References 21 publications

Osteogenic Induction of Wharton’s Jelly-Derived Mesenchymal Stem Cell for Bone Regeneration: A Systematic Review

Osteogenic Induction of Wharton’s Jelly-Derived Mesenchymal Stem Cell for Bone Regeneration: A Systematic Review

Aldehyde dehydrogenase activity of Wharton jelly mesenchymal stromal cells: isolation and characterization

Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation

Contact Info

Product

Resources

About